441 related articles for article (PubMed ID: 25421275)
1. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
[TBL] [Abstract][Full Text] [Related]
2. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
3. Validation of analytic methods for biomarkers used in drug development.
Chau CH; Rixe O; McLeod H; Figg WD
Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475
[TBL] [Abstract][Full Text] [Related]
4. Theory and practice of clinical pharmacodynamics in oncology drug development.
Parchment RE; Doroshow JH
Semin Oncol; 2016 Aug; 43(4):427-35. PubMed ID: 27663474
[TBL] [Abstract][Full Text] [Related]
5. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
6. Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland.
Youssoufian H
IDrugs; 2010 Dec; 13(12):833-5. PubMed ID: 21154137
[TBL] [Abstract][Full Text] [Related]
7. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Gingras I; Salgado R; Ignatiadis M
Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets in cancer therapy.
Kummar S; Doroshow JH
Expert Rev Anticancer Ther; 2013 Mar; 13(3):267-9. PubMed ID: 23477512
[TBL] [Abstract][Full Text] [Related]
10. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery.
El Bairi K; Atanasov AG; Amrani M; Afqir S
Biomed Pharmacother; 2019 Jan; 109():2492-2498. PubMed ID: 30551510
[TBL] [Abstract][Full Text] [Related]
11. Introduction to special issue on biomarker-based clinical trial designs in oncology.
Sargent DJ; Mandrekar S; Grothey A
Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295
[No Abstract] [Full Text] [Related]
12. Targeted approaches to childhood cancer: progress in drug discovery and development.
Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
14. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
Alymani NA; Smith MD; Williams DJ; Petty RD
Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
[TBL] [Abstract][Full Text] [Related]
16. Editorial (Thematic Issue: The Predictive Pathology in the Target Therapy Era).
Franco R; Cantile M
Curr Drug Targets; 2017; 18(1):2-3. PubMed ID: 27991404
[No Abstract] [Full Text] [Related]
17. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
Hansen AR; Siu LL
JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
[No Abstract] [Full Text] [Related]
19. Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream.
Lyman GH; Moses HL
J Clin Oncol; 2016 Jun; 34(17):2061-6. PubMed ID: 27069080
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
